Malin Corporation

Malin Corporation Equity

The The Equity of Malin Corporation (MLC.IR) as of Sep 27, 2026 is 193.20 M EUR. In the previous year, The Equity was 109.50 M EUR — a change of 76.44% (higher).

Equity

193.20 MEUR

YoY

76.44%

Last updated:

In 2026, Malin Corporation's equity was 193.20 M EUR, a 76.44% increase from the 109.50 M EUR equity in the previous year.

The Malin Corporation Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
207.30 M EUR
Jan 1, 2018
160.50 M EUR
Jan 1, 2019
168.90 M EUR
Jan 1, 2020
279.80 M EUR
Jan 1, 2021
218.90 M EUR
Jan 1, 2022
283.10 M EUR
Jan 1, 2023
109.50 M EUR
Jan 1, 2024
193.20 M EUR
The Malin Corporation Equity history
YEAREquityYoY
193.20 MEUR+76.44%
109.50 MEUR-61.32%
283.10 MEUR+29.33%
218.90 MEUR-21.77%
279.80 MEUR+65.66%
168.90 MEUR+5.23%
160.50 MEUR-22.58%
207.30 MEUR-27.52%
286.00 MEUR-18.12%
349.30 MEUR—
Access this data via the Eulerpool API

Malin Corporation Stock analysis

What does Malin Corporation do? Malin Corporation PLC is an Irish company that was founded in 2014. The company is a subsidiary of Elan, a company specialized in pharmaceutical development. Malin has focused its business model on identifying, supporting, and scaling startup companies. The company supports and invests in startups in the biopharmaceutical industry that focus on new and innovative therapies. Malin offers help and advice to its portfolio companies in product development and business organization. The company has invested in various areas of the biopharmaceutical industry. For example, it has supported YumaTherapeutics, a company focused on the discovery and development of novel therapeutics for infectious diseases. Malin has also provided financial support to Seres Therapeutics, which has built a pipeline of therapeutics targeting the microbiome, the collection of microorganisms living in the gut. Malin has invested in Inivata, a company specialized in the development of cancer diagnostics. Furthermore, Malin has various other companies in its investment pipeline that deal with a variety of therapeutic possibilities. This includes therapies for genetic diseases and inherited metabolic disorders, as well as applications of gene therapy and immunotherapy. Malin Corporation PLC has also developed its own products and partnerships. One of these partnerships is with Novaerus, another Irish company specialized in the development of air purification systems. Novaerus systems use a plasma-based ion system to destroy bacteria, viruses, and fungi in the air, thus preventing infections. Malin is also involved in research collaborations. One collaboration is with University College Dublin, where Malin provides financial support for research on biopharmaceutical processes. The history of Malin Corporation PLC is characterized by a strong commitment to supporting innovative companies in the biopharmaceutical industry. The company aims to promote the growth and development of startups, offering not only financial support but also advice and expertise. Malin has diversified its investments in various areas of the biopharmaceutical industry and focuses on promoting products that improve people's health and well-being. The company has also developed its own products and partnerships to bring new technologies and therapies to the market. Overall, Malin Corporation PLC is a company specialized in supporting and promoting startups in the biopharmaceutical industry. The company is committed to developing products and therapies that have the potential to improve and prolong people's lives. Malin Corporation is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Malin Corporation's Equity

Malin Corporation's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Malin Corporation's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Malin Corporation's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Malin Corporation's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Malin Corporation’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Malin Corporation stock

The Equity of Malin Corporation is 193.20 M EUR in 2026.

The Equity of Malin Corporation changed from 109.50 M EUR to 193.20 M EUR, representing a 76.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Malin Corporation since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Malin Corporation historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Malin Corporation

All Key Metrics — Malin Corporation